ChemoCentryx to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

ChemoCentryx, Inc. (Nasdaq: CCXI) announced that its CEO, Thomas J. Schall, Ph.D., will present at two upcoming investor events: the 39th Annual J.P. Morgan Healthcare Conference on January 13 at 11:40 a.m. ET, and the H.C. Wainwright Virtual BioConnect Conference, with an on-demand presentation available from January 11. Additionally, a Clinical Trial Panel Discussion will take place on January 11 at 12:00 p.m. ET. Live webcasts and replays can be accessed on the company’s website. ChemoCentryx is developing therapies for inflammatory diseases and cancer, with its lead drug, avacopan, under review by FDA and EMA.

MOUNTAIN VIEW, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences and participate in a panel discussion hosted by former FDA Commissioner, Scott Gottlieb, M.D.:

• 39th Annual J.P. Morgan Healthcare Conference
  Wednesday, January 13 at 11:40 a.m. Eastern Time
  
  
• H.C. Wainwright Virtual BioConnect Conference
  On-demand presentation available beginning Monday, January 11 at 6:00 a.m. Eastern Time
  

• Clinical Trial Panel Discussion at the H.C. Wainwright Virtual BioConnect Conference
  Monday, January 11 at 12:00 p.m. Eastern Time

Live audio webcasts of the J.P. Morgan presentation and H.C. Wainwright Clinical Trials Panel and on-demand presentation can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. Replays of both the J.P. Morgan and H.C. Wainwright presentations will be available on the Company's website for two weeks following the respective presentation dates.

About ChemoCentryx

ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration, along with a Marketing Authorization Application by the European Medicines Agency. Avacopan is also in late-stage clinical development for the treatment of Hidradenitis Suppurativa and C3 glomerulopathy (C3G).

ChemoCentryx also has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Contacts:

Susan M. Kanaya
Executive Vice President,
Chief Financial and Administrative Officer
investor@chemocentryx.com

Media:
Stephanie Tomei
408.234.1279
media@chemocentryx.com

Investors:
Lee Roth, Burns McClellan
212.213.0006
lroth@burnsmc.com

FAQ

When will ChemoCentryx present at the J.P. Morgan Healthcare Conference?

ChemoCentryx will present at the J.P. Morgan Healthcare Conference on January 13 at 11:40 a.m. Eastern Time.

What date is the H.C. Wainwright Virtual BioConnect Conference presentation?

The H.C. Wainwright Virtual BioConnect Conference presentation is available on-demand starting January 11 at 6:00 a.m. Eastern Time.

What is the purpose of the Clinical Trial Panel Discussion at the H.C. Wainwright Conference?

The Clinical Trial Panel Discussion at the H.C. Wainwright Conference will take place on January 11 at 12:00 p.m. Eastern Time, focusing on clinical trials.

Where can I access the webcasts of ChemoCentryx's presentations?

Live audio webcasts and replays of the presentations can be accessed through the Investors section of ChemoCentryx's website.

What is the status of ChemoCentryx's lead drug candidate, avacopan?

Avacopan is under review by the FDA for ANCA-associated vasculitis and has a Marketing Authorization Application with the EMA.